Intelligence Feed event · Equity · 2026-09-21

    Bristol Myers Squibb growth portfolio reaches 60% of revenue with 153% Q2 EPS growth

    Question

    Bristol Myers Squibb growth portfolio reaches 60% of revenue with 153% Q2 EPS growth

    Direct answer

    Bristol Myers Squibb delivered $12.9 billion in quarterly revenue, driven by 15% growth in its next-generation drug portfolio. New products now account for nearly 60% of aggregate revenue, reducing operational dependence on legacy franchises facing patent expirations. Despite a 17% year-to-date share price advance and 153% EPS growth in Q2, BMY continues to trade at a discount multiple to major biopharma peers including Merck, Pfizer, and AbbVie, presenting fundamental valuation dispersion within the healthcare sector.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-21
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Bristol Myers Squibb growth portfolio reaches 60% of revenue with 153% Q2 EPS growth”, revision 1, evidence through 2026-09-21. https://marketontology.com/market-events/2026-09-21/bristol-myers-squibb-growth-portfolio-reaches-60-of-revenue-with-153-q2-eps-grow-b96c58

    EQUITY
    Bristol Myers Squibb growth portfolio reaches 60% of revenue with 153% Q2 EPS growth
    Bristol Myers Squibb delivered $12.9 billion in quarterly revenue, driven by 15% growth in its next-generation drug portfolio. New products now account for nearly 60% of aggregate revenue, reducing operational dependence on legacy franchises facing patent expirations. Despite a 17% year-to-date share price advance and 153% EPS growth in Q2, BMY continues to trade at a discount multiple to major biopharma peers including Merck, Pfizer, and AbbVie, presenting fundamental valuation dispersion within the healthcare sector.
    BMYXLV
    Impact
    67
    SEP 21
    SIG
    85%
    BMYXLV
    Bristol Myers Squibb growth portfolio reaches 60% of revenue with 153% Q2 EPS growth
    Bristol Myers Squibb delivered $12.9 billion in quarterly revenue, driven by 15% growth in its next-generation drug portfolio. New products now account for nearly 60% of aggregate revenue, reducing operational dependence on legacy franchises facing patent expirations. Despite a 17% year-to-date share price advance and 153% EPS growth in Q2, BMY continues to trade at a discount multiple to major biopharma peers including Merck, Pfizer, and AbbVie, presenting fundamental valuation dispersion within the healthcare sector.
    → Expansion of high-margin growth drug revenues to 60% of product mix offsets patent cliff expiry risk and compresses BMY's forward P/E valuation discount against XLV peers.
    Impact
    Bristol Myers Squibb delivered $12.9 billion in quarterly revenue, driven by 15% growth in its next-generation drug portfolio. New products now account for nearly 60% of aggregate revenue, reducing operational dependence on legacy franchises facing patent expirations. Despite a 17% year-to-date share price advance and 153% EPS growth in Q2, BMY continues to trade at a discount multiple to major biopharma peers including Merck, Pfizer, and AbbVie, presenting fundamental valuation dispersion within the healthcare sector.
    Affected
    BMYXLV
    Transmission
    Expansion of high-margin growth drug revenues to 60% of product mix offsets patent cliff expiry risk and compresses BMY's forward P/E valuation discount against XLV peers.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    BMYforward earnings multiple rerating on product mix shiftUp1-4wQ2 revenue reached $12.9B with 153% EPS growth and growth portfolio reaching 60% of total revenue.
    XLVbiopharma constituent earnings durabilityUp1-4wBMY is a core constituent of the broad healthcare index ETF.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XLVUpagreed169.01 2026-09-21+0.52%+1.33%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month